[1]
Anderson JL, Askins JC, Gilbert EM, Miller RH, Keefe DL, Somberg JC, Freedman RA, Haft LR, Mason JW, Lessem JN. Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: a double-blind, randomized, placebo-controlled evaluation of two doses. Journal of the American College of Cardiology. 1986 Oct:8(4):752-62
[PubMed PMID: 2428852]
Level 1 (high-level) evidence
[2]
deSouza IS, Martindale JL, Sinert R. Antidysrhythmic drug therapy for the termination of stable, monomorphic ventricular tachycardia: a systematic review. Emergency medicine journal : EMJ. 2015 Feb:32(2):161-7. doi: 10.1136/emermed-2013-202973. Epub 2013 Sep 16
[PubMed PMID: 24042252]
Level 1 (high-level) evidence
[3]
McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Annals of internal medicine. 2003 Dec 16:139(12):1018-33
[PubMed PMID: 14678922]
[4]
Zimetbaum PJ, Josephson ME. Amiodarone versus sotalol for atrial fibrillation. The New England journal of medicine. 2005 Aug 11:353(6):627-30; author reply 627-30
[PubMed PMID: 16094764]
[5]
Gomes JA, Ip J, Santoni-Rugiu F, Mehta D, Ergin A, Lansman S, Pe E, Newhouse TT, Chao S. Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. Journal of the American College of Cardiology. 1999 Aug:34(2):334-9
[PubMed PMID: 10440141]
Level 1 (high-level) evidence
[6]
Shah A, Moon-Grady A, Bhogal N, Collins KK, Tacy T, Brook M, Hornberger LK. Effectiveness of sotalol as first-line therapy for fetal supraventricular tachyarrhythmias. The American journal of cardiology. 2012 Jun 1:109(11):1614-8. doi: 10.1016/j.amjcard.2012.01.388. Epub 2012 Mar 22
[PubMed PMID: 22444730]
[7]
Somberg J, Molnar J. Sotalol versus Amiodarone in Treatment of Atrial Fibrillation. Journal of atrial fibrillation. 2016 Feb-Mar:8(5):1359. doi: 10.4022/jafib.1359. Epub 2016 Feb 29
[PubMed PMID: 27909477]
[8]
Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD Jr, Raisch DW, Ezekowitz MD, Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. The New England journal of medicine. 2005 May 5:352(18):1861-72
[PubMed PMID: 15872201]
[9]
Batul SA, Gopinathannair R. Intravenous Sotalol - Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal. Journal of atrial fibrillation. 2017 Feb-Mar:9(5):1499. doi: 10.4022/jafib.1499. Epub 2017 Feb 28
[PubMed PMID: 29250266]
[10]
DeMarco KR, Yang PC, Singh V, Furutani K, Dawson JRD, Jeng MT, Fettinger JC, Bekker S, Ngo VA, Noskov SY, Yarov-Yarovoy V, Sack JT, Wulff H, Clancy CE, Vorobyov I. Molecular determinants of pro-arrhythmia proclivity of d- and l-sotalol via a multi-scale modeling pipeline. Journal of molecular and cellular cardiology. 2021 Sep:158():163-177. doi: 10.1016/j.yjmcc.2021.05.015. Epub 2021 May 29
[PubMed PMID: 34062207]
[11]
Lei M, Wu L, Terrar DA, Huang CL. Modernized Classification of Cardiac Antiarrhythmic Drugs. Circulation. 2018 Oct 23:138(17):1879-1896. doi: 10.1161/CIRCULATIONAHA.118.035455. Epub
[PubMed PMID: 30354657]
[12]
Hanyok JJ. Clinical pharmacokinetics of sotalol. The American journal of cardiology. 1993 Aug 12:72(4):19A-26A
[PubMed PMID: 8346722]
[13]
Samanta R, Thiagalingam A, Turner C, Lakkireddy DJ, Kovoor P. The Use of Intravenous Sotalol in Cardiac Arrhythmias. Heart, lung & circulation. 2018 Nov:27(11):1318-1326. doi: 10.1016/j.hlc.2018.03.017. Epub 2018 Mar 29
[PubMed PMID: 29853342]
[14]
Kopelman HA, Woosley RL, Lee JT, Roden DM, Echt DS. Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease. The American journal of cardiology. 1988 May 1:61(13):1006-11
[PubMed PMID: 3284316]
[15]
Anderson JL, Prystowsky EN. Sotalol: An important new antiarrhythmic. American heart journal. 1999 Mar:137(3):388-409
[PubMed PMID: 10047618]
[16]
Finks SW, Rogers KC, Manguso AH. Assessment of sotalol prescribing in a community hospital: opportunities for clinical pharmacist involvement. The International journal of pharmacy practice. 2011 Aug:19(4):281-6. doi: 10.1111/j.2042-7174.2011.00094.x. Epub 2011 Mar 15
[PubMed PMID: 21733016]
[17]
O'Hare MF, Murnaghan GA, Russell CJ, Leahey WJ, Varma MP, McDevitt DG. Sotalol as a hypotensive agent in pregnancy. British journal of obstetrics and gynaecology. 1980 Sep:87(9):814-20
[PubMed PMID: 7426541]
[19]
Biswas M, Levy A, Weber R, Tarakji K, Chung M, Noseworthy PA, Newton-Cheh C, Rosenberg MA. Multicenter Analysis of Dosing Protocols for Sotalol Initiation. Journal of cardiovascular pharmacology and therapeutics. 2020 May:25(3):212-218. doi: 10.1177/1074248419887710. Epub 2019 Nov 10
[PubMed PMID: 31707834]
[20]
Campleman SL, Brent J, Pizon AF, Shulman J, Wax P, Manini AF, Toxicology Investigators’ Consortium (ToxIC). Drug-specific risk of severe QT prolongation following acute drug overdose. Clinical toxicology (Philadelphia, Pa.). 2020 Dec:58(12):1326-1334. doi: 10.1080/15563650.2020.1746330. Epub 2020 Apr 7
[PubMed PMID: 32252558]
[21]
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022 May 3:79(17):e263-e421. doi: 10.1016/j.jacc.2021.12.012. Epub 2022 Apr 1
[PubMed PMID: 35379503]
Level 1 (high-level) evidence
[22]
Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, Daubert JP, de Chillou C, DePasquale EC, Desai MY, Estes NAM 3rd, Hua W, Indik JH, Ingles J, James CA, John RM, Judge DP, Keegan R, Krahn AD, Link MS, Marcus FI, McLeod CJ, Mestroni L, Priori SG, Saffitz JE, Sanatani S, Shimizu W, van Tintelen JP, Wilde AAM, Zareba W. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart rhythm. 2019 Nov:16(11):e301-e372. doi: 10.1016/j.hrthm.2019.05.007. Epub 2019 May 9
[PubMed PMID: 31078652]
Level 3 (low-level) evidence